[Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy].


AIM To study the impact of infusion therapy with the metabolic modulator remaxol on lipid metabolic parameters and target organ (liver, kidney) function in metabolic syndrome (MS). SUBJECTS AND METHODS The investigation enrolled 90 patients (54 men and 36 women) with primary nonalcoholic steatohepatitis that was associated with insulin-resistance and MS… (More)